| Erica Lyndrup Herzog, MD | |
|
789 Howard Ave, Winchester Chest Clinic - Fitkin Building - 2nd Floor, New Haven, CT 06519-1304 | |
| (203) 785-4198 | |
| (203) 785-3826 |
| Full Name | Erica Lyndrup Herzog |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 27 Years |
| Location | 789 Howard Ave, New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962485029 | NPI | - | NPPES |
| 001396250 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 039625 (Connecticut) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 039625 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yale University | 9436061736 | 2241 |
News Archive
ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.
A Loyola Medicine study is providing further evidence that floppy eyelids may be a sign of sleep apnea.
New research published in The Journal of Physiology has indicated why people with paralysis of their limbs and torso are more likely to suffer from sleep apnoea. This knowledge could be used to develop much-need targeted therapies.
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
› Verified 1 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.
A Loyola Medicine study is providing further evidence that floppy eyelids may be a sign of sleep apnea.
New research published in The Journal of Physiology has indicated why people with paralysis of their limbs and torso are more likely to suffer from sleep apnoea. This knowledge could be used to develop much-need targeted therapies.
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erica Lyndrup Herzog, MD 300 George Street, 6th Floor Po Box 9805, New Haven, CT 06536-0805 Ph: () - | Erica Lyndrup Herzog, MD 789 Howard Ave, Winchester Chest Clinic - Fitkin Building - 2nd Floor, New Haven, CT 06519-1304 Ph: (203) 785-4198 |
News Archive
ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.
A Loyola Medicine study is providing further evidence that floppy eyelids may be a sign of sleep apnea.
New research published in The Journal of Physiology has indicated why people with paralysis of their limbs and torso are more likely to suffer from sleep apnoea. This knowledge could be used to develop much-need targeted therapies.
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
› Verified 1 days ago
Dr. Brian Christopher Cambi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 333 Cedar St, Dcb 3, New Haven, CT 06510 Phone: 203-785-4129 Fax: 203-737-2437 | |
Ms. Maryam Gondal, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 330 Cedar Street, Bb 114, New Haven, CT 06510 Phone: 203-785-4184 | |
Matthew Joseph Mcconnell, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 333 Cedar St, Ynhh Internal Medicine-gi,section Of Digestive Diseases, New Haven, CT 06510 Phone: 203-785-7012 | |
Marie Anjeliese Rodriguez, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Dr. Margaret M Xu, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Carola Marte, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1450 Chapel St, Haelen Center, New Haven, CT 06511 Phone: 203-789-4135 Fax: 203-867-5241 | |
Jeanette M Tetrault, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Long Wharf Dr, New Haven, CT 06511 Phone: 203-781-4600 Fax: 203-781-4624 |